Nyctea Technologies

And we are off! Nyctea participated in the #Innovatorsummit2024 in Mountain View, CA marking the beginning of the 2024 MedTech Innovator and BioTools Innovator Accelerator program. The largest life sciences accelerator in the world! We are very excited for the journey ahead together with a cohort of really inspiring entrepreneurs, industry partners and leaders to learn, develop and grow our company further. #IamanInnovator #InnovatorSummit2024 #lifesciencetools #biotools #techbio

The Nyctea Team is getting ready for the upcoming BioTools Innovator Summit in Mountain View, CA! BioTools Innovator Accelerator is a four-month program providing in-depth, customized mentorship from senior industry leaders, funding opportunities, and engagement with peers and advisors. We are so proud to be selected out of +300 applicants. We are the only company from Sweden and one of three from EU! We really look forward to meet the other companies in the cohort: Anvil Diagnostics, Autolomous, Axolotl Biosciences, CellRev, Cerillo, CytoRecovery, Inc., EmGenisys, EpiPaws, FemtoFluidics, Life Magnetics, Narwhal Bio Inc., Pluto Bio, Polybiomics Inc., QurCan Therapeutics Inc., React4life, Redbud Labs, Ryght, Sarcura , and Syenex Pressrelease: https://lnkd.in/dFDVpgXd The result of amazing teamwork and best backing! Maria Kiriakidou, Hanna Tranchell, Oliver Olsson, Armaghan R., Christine Ellis, Andreas Dahlin, Marie Callemyn, Elin Bång, Bagus Santoso, Gustav Ferrand-Drake, BioVentureHub, Chalmers Ventures, Skagerack Ventures, Pontus Pettersson, Daniel Langkilde

At Nyctea Technologies we are super excited about being selected for the BioTools Innovator cohort 2024! Looking forward to participate! 🚀

Nyctea participated in the BioTools Innovator Virtual Pitch Event!   BioTools Innovator is an accelerator intended to support entrepreneurs that are developing a broad spectrum of biotechnology products, platforms and services that are enabling the future of healthcare.   We are proud to be one of a few selected companies for the event. It was a great opportunity for us to pitch and get feedback from investors and industry leaders and also to meet really interesting emerging biotech companies! 

Nyctea is happy to announce that Armaghan R. has joined our team as Research Assistant! ⚡⚡   She recently graduated from Gothenburg University where she wrote her Master thesis on a project about analytical electrochemistry in cells. We are thrilled to have her on the team as her skills and experience will be highly useful in the continued development of the Nyctea platform for improved purification of Advanced Therapeutical Modality Products such as cell and gene therapies! 🧫🧬   Welcome onboard Armaghan!

Hanna Tranchell is joining Nyctea as Project Manager! ⚡⚡   We are very happy that our talented MSc thesis student from Chalmers tekniska högskola is joining us full-time.   We look forward to continuing building products for efficient purification of biopharmaceuticals with you! 🚀

Nyctea Enters Research Collaboration with AstraZeneca!   We will apply our Nyctea® platform technology to improve the purification process for a drug compound in AstraZeneca's Research and Development program.   This is a Big milestone for Nyctea - our first collaboration agreement with a biopharmaceutical company. We look forward to deliver leap improvements in efficient and sustainable manufacturing of advanced biopharmaceuticals.   Made possible thanks to hard work of a dedicated team: Maria Kiriakidou Hanna Tranchell Oliver Olsson Armaghan Romiani Christine Ellis Elin Bång, Andreas Dahlin Gustav Ferrand-Drake Also thanks to our fantastic workplace and the people at BioVentureHub   https://lnkd.in/dzAPQwgw

Nyctea is proud to be on the front page of latest issue of Elektroniktidningen Sverige AB! ⚡📰⭐ https://lnkd.in/dzxg2ZDr Read about us in the Medtech section and other interesting articles. Thanks Jan Tångring for the interview and writing a great article about us! Free to subscribe if your into electronics: etn.se/pren Andreas Dahlin Maria Kiriakidou Oliver Olsson Hanna Tranchell Christine Ellis Armaghan Romiani

Nyctea Technologies is on Ny Teknik #33listan!! ⚡   We are so happy to be named among the most interesting and promising new companies in Sweden 2023! The recognition comes in a year when Nyctea has moved into BioVentureHub and sold our product to some of the largest biopharma companies in the world.    Founder and CEO Gustav Ferrand-Drake del Castillo - "We are honored to be listed on #33listan. It was a dream of mine to qualify on this list back when we founded the company. This gives us energy to keep pushing the boundaries of innovation and redefine pharmaceutical manufacturing!"   Thanks to the Nyctea team and support from our investors, Pontus, Daniel Langkilde, SkagerackVentures and Chalmers Ventures!

Nyctea has a new team member! ⭐   We are thrilled to announce Christine will perform her Master Thesis project with us! She holds a BSc in Biochemistry from Virginia Tech and was working in the medical device industry before starting the Biotechnology program at Chalmers.   She will evaluate Nyctea’s product for non-invasive purification of new biopharmaceutical modalities using electrochemistry. Together we are pushing the boundary of fast and cost effective production of biological pharmaceuticals. 🦉 ⚡ 🧪🧫   Christine, what is most exciting about your Master thesis project at Nyctea? 🗨 Learning a new subject! Electrochemistry is a topic I’ve heard about but it’s only been passively relevant in my courses and I’m excited to become more familiar with its nuances and roles in biological systems. Happy to have you onboard Christine! 🙌